Investing Profile

Michael Rome

VCInvestor

Managing Director & Co-Head of Therapeutics Investing at Foresite Capital

Your Intro Paths to Michael Rome

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Michael is a member of

UCLA Network

34 CONNECTIONS

California Institute of Technology Network

16 CONNECTIONS

Find Michael Rome on

Current Investing Position

Foresite Capital Managing Director

Investment Range

$100K - $5.0M

Sweet Spot

$1.5M

Investments On Record

Current Fund Size

$668M

Michael Rome is on these Sector & Stage Rankings

Michael Rome's Investments On Record (7)

Company	StageDateRound Size	Total Raised
Alumis	Series CMar 2024$260M Series AMay 2021$70M	$330M
Co-investors: Jim Tananbaum (Foresite Capital), Vikram Bajaj (Foresite Capital), Richard Gaster (venBio)
Remix Therapeutics	Series UnknownJan 2024$60M Series BMay 2022$70M Series ADec 2020$65M	$210M
Co-investors: Kevin Bitterman (Atlas Venture), Kristina Burow (ARCH Venture Partners), Leon Chen (The Column Group), Peter Svennilson (The Column Group)
CG Oncology	Series FAug 2023$110M	$110M
Co-investors: Shane Neman
XinThera	Series BAug 2021$50M	$50M
Co-investors: Carl Gordon (OrbiMed), Jim Tananbaum (Foresite Capital)
Theseus Pharmaceuticals	Series BApr 2021$100M	$100M
Co-investors: Carl Gordon (OrbiMed)
Kinnate Biopharma	Series CAug 2020$98M Series BDec 2019$75M Series AApr 2018$22M	$200M
Co-investors: Carl Gordon (OrbiMed), Brett Zbar (General Atlantic), Peter Kolchinsky (RA Capital)
Nurix Therapeutics	Private EquityMar 2020$120M	$150M
Co-investors: David Goeddel (The Column Group)